TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage

Cell Death Differ. 2019 May;26(5):918-931. doi: 10.1038/s41418-018-0168-6. Epub 2018 Jul 26.

Abstract

Protein acetylation and deacetylation events are finely regulated by lysine-acetyl-transferases and lysine-deacetylases and constitute an important tool for the activation or inhibition of specific cellular pathways. One of the most important lysine-acetyl-transferases is p300, which is involved in the regulation of gene expression, cell growth, DNA repair, differentiation, apoptosis, and tumorigenesis. A well-known target of p300 is constituted by the tumor suppressor protein p53, which plays a critical role in the maintenance of genomic stability and whose activity is known to be controlled by post-translational modifications, among which acetylation. p300 activity toward p53 is negatively regulated by the NAD-dependent deacetylase SIRT1, which deacetylates p53 preventing its transcriptional activation and the induction of p53-dependent apoptosis. However, the mechanisms responsible for p53 regulation by p300 and SIRT1 are still poorly understood. Here we identify the nucleosome assembly protein TSPY-Like 2 (TSPYL2, also known as TSPX, DENTT, and CDA1) as a novel regulator of SIRT1 and p300 function. We demonstrate that, upon DNA damage, TSPYL2 inhibits SIRT1, disrupting its association with target proteins, and promotes p300 acetylation and activation, finally stimulating p53 acetylation and p53-dependent cell death. Indeed, in response to DNA damage, cells silenced for TSPYL2 were found to be defective in p53 activation and apoptosis induction and these events were shown to be dependent on SIRT1 and p300 function. Collectively, our results shed new light on the regulation of p53 acetylation and activation and reveal a novel TSPYL2 function with important implications in cancerogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Acetylation / drug effects
  • Apoptosis / drug effects
  • Camptothecin / pharmacology
  • Cell Proliferation / drug effects
  • Chromatin Assembly and Disassembly / genetics
  • DNA Damage / drug effects
  • DNA-Binding Proteins
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / pharmacology
  • E1A-Associated p300 Protein / genetics*
  • Etoposide / pharmacology
  • Gemcitabine
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Nuclear Proteins / genetics*
  • Protein Processing, Post-Translational / genetics
  • Sirtuin 1 / genetics*
  • Transcriptional Activation / drug effects
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • DNA-Binding Proteins
  • Nuclear Proteins
  • TSPYL2 protein, human
  • Tumor Suppressor Protein p53
  • Deoxycytidine
  • Etoposide
  • E1A-Associated p300 Protein
  • EP300 protein, human
  • SIRT1 protein, human
  • Sirtuin 1
  • Camptothecin
  • Gemcitabine